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Abstract
Background: Diabetes treatment may differ by region and patients’ socioeconomic position. This may be particularly true
for newer drugs. However, data are highly limited.
Methods: We examined pooled individual data of two population-based German studies, KORA F4 (Cooperative Health
Research in the Region of Augsburg, south), and the HNR (Heinz Nixdorf Recall study, west) both carried out 2006 to 2008.
To ascertain the association between region and educational level with anti-hyperglycemic medication we fitted poisson
regression models with robust error variance for any and newer anti-hyperglycemic medication, adjusting for age, sex,
diabetes duration, BMI, cardiovascular disease, lifestyle, and insurance status.
Results: The examined sample comprised 662 participants with self-reported type 2 diabetes (KORA F4: 83 women, 111
men; HNR: 183 women, 285 men). The probability to receive any anti-hyperglycemic drug as well as to be treated with
newer anti-hyperglycemic drugs such as insulin analogues, thiazolidinediones, or glinides was significantly increased in
southern compared to western Germany (prevalence ratio (PR); 95% CI: 1.12; 1.02–1.22, 1.52;1.10–2.11 respectively).
Individuals with lower educational level tended to receive anti-hyperglycemic drugs more likely than their better educated
counterparts (PR; 95% CI univariable: 1.10; 0.99–1.22; fully adjusted: 1.10; 0.98–1.23). In contrast, lower education was
associated with a lower estimated probability to receive newer drugs among those with any anti-hyperglycemic drugs (PR
low vs. high education: 0.66; 0.48–0.91; fully adjusted: 0.68; 0.47–0.996).
Conclusions: We found regional and individual social disparities in overall and newer anti-hyperglycemic medication which
were not explained by other confounders. Further research is needed.
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Introduction
Regional differences in treatment patterns, in particular for drug
prescriptions, receive growing attention in several countries [1,2].
However, data are still scarce. This is also true for regional
differences in anti-hyperglycemic treatment.
During the last years, new treatment options for type 2 diabetes
arose. While newer medications such as glitazones, glinides and
insulin analogues enrich treatment options, metformin (bigua-
nides) remains the oral drug of first choice in type 2 diabetes
treatment [3,4]. Little is known about regional differences in
prescriptions of newer anti-hyperglycemic drugs.
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Furthermore, the association between individuals’ socioeco-
nomic position and patterns of medication are of increasing
interest. Despite the wide literature on the general topic,
socioeconomic factors are rarely examined in association with
drug treatment, particularly in the context of anti-hyperglycemic
medication. We found only one Canadian study which could show
that patients’ income had an important impact on the probability
of receiving newer thiazolidinediones (TZDs) [5,6].
In Germany, about 90% of all individuals are covered by a
statutory health insurance which reimburses all medical services
covering both newer and older diabetes medications [7,8].
However, in order to provide economic efficiency, benchmarks
for budgeting are defined in collective agreements between
statutory health insurances and physicians [8]. Resident physicians
can also conclude selective contracts with providers of statutory
health insurances which may include further tools for guidance.
About 10% of the population are privately health insured (e.g. self-
employed individuals, civil servants and their family members).
These private health insurances impose less economic regulations
on physicians and offer some extra services basically to provide
more convenience to patients (e.g. single-bed rooms for inpatient
treatment, medical attention by a chief physician). For statutory
health insured patients, a disease management program (DMP) for
diabetes has been implemented in 2002 [9], covering a large
proportion of voluntarily participating patients with diabetes. This
DMP harmonizes diabetes management and provides financial
compensation for (also voluntarily) participating physicians.
Within the DMP program quality standards have been defined
such as HbA1c targets, prevention of hypoglycemic episodes and
other emergency situations, treatment of hypertension, reduction
of tobacco consumption among patients, increasing numbers of
patients who receive disease-specific education [10]. Physicians are
regularly informed about the average achievement of these goals
among their patients in comparison to all registered patients.
Regarding anti-hyperglycemic treatment, metformin is explicitly
recommended in overweight patients with oral monotherapy.
However, individual treatment decisions (in order to reach the
aforementioned goals) are supported [10]. Thus, it may be
assumed that under these conditions, a rather homogenous
treatment pattern exists. However, in an earlier study of the
Diabetes Collaborative Research of Epidemiologic Studies (DIAB-
CORE) consortium, based on pooled individual population-based
data, self-reported anti-hyperglycemic medication differed across
regions, without showing a clear geographical pattern [11]. Also,
the regional population-based studies used for analysis were
conducted between 1999 and 2006, when disease management
programs were not widespread. In addition, newer treatment
options only just arose so that disparities in insulin analogues or
newer oral anti-hyperglycemic drugs have not yet been examined.
The aim of our study was to examine (i) if the previously found
regional differences in anti-hyperglycemic treatment still exist at a
more recent date, (ii) if general regional disparities in treatment
patterns exist, e.g. the proportion of patients who receive anti-
hyperglycemic drugs, but also drug patterns, e.g. prescription of
newer drugs, and (iii) if treatment patterns differ with patients’
individual socioeconomic status. We used population-based follow-
up data from two German regions, one in the south and one in the
west which have been carried out in a comparable time frame
between 2006 and 2008.
Materials and Methods
Ethics Statement
The Heinz Nixdorf Recall (HNR) study, including the study
protocols for participant recruitment, and the informed consent
for participants, were approved by the institutional local ethical
committees (baseline: Medical faculty University of Essen; follow-
up: Medical faculty University of Duisburg-Essen). A quality
management system according to European industrial norms (DIN
EN ISO 9001:2000) was applied. All participants gave their
written consent.
In the KORA studies the participants provided written
informed consent. The ethics committee (Bayerische Landesärzte-
kammer) approved the study and approved the consent procedure
including patient information materials and consent form.
Study population and ascertainment of diabetes
Two studies were included: the first follow-up of the Heinz
Nixdorf Recall Study (HNR) which was conducted in the adjacent
cities of Essen, Bochum and Mülheim of the Ruhr-Area (North
Rhine-Westphalia, western Germany) and the first follow-up of the
Cooperative Health Research in the Region of Augsburg Survey
(KORA F4) study, covering the city of Augsburg and two
surrounding rural districts (Bavaria, southern Germany).
4,261 participants attended baseline examinations in KORA S4
(1999–2001; 25–74 years; response 66.8%) [12] and 4.814
participants in HNR (2000–2003; 45–74 years; response 55.8%)
[13]. Of these, 3080 participated in the F4 follow-up study in
KORA (2006–2008, response 79.6%) [14], and 4,146 in HNR
(2005–2008, 86.1% response) [15,16]. To allow for comparability,
people aged at least 50 years at follow-up were included. Further
details of the KORA F4 study and HNR have been described
elsewhere [16–18].
Prevalent diabetes was defined based on self-report of a
physician’s diagnosis or self-reported anti-hyperglycemic treatment
(insulin or oral glucose lowering agents). Study objectives address
mainly type 2 diabetes. Since distinction of type 1 and type 2
diabetes is not highly valid in self-reports, subjects with self-
reported age at diagnosis before the age of 30 years – possibly
cases with type 1 diabetes - were excluded. Self-reported age at
diagnosis was ascertained in both studies. Diabetes duration was
calculated as the timeframe between age at follow-up and age at
diagnosis.
Overall, 199 participants had self-reported diabetes in KORA
F4 and 492 in HNR. After exclusion of 26 participants with
missing information in relevant data or limited comparability
(n = 5 in KORA F4, n = 24 in HNR), 194 individuals with type 2
diabetes from KORA F4 and 468 participants from HNR
remained for analysis.
Assessment and classification of prescribed anti-
hyperglycemic drugs
Participants were asked to bring the original packages of all
medications used during the seven days prior to the interview to
the examination center. Using a scanning system, unique
pharmaceutical identifiers were recorded assigning ATC codes
(Anatomical Therapeutic Chemical Classification System) which
are displayed by 7 characters. The first three characters of the
ATC code ‘‘A10’’ indicate any kind of diabetes medication. Under
‘‘A10A’’ all types of insulin are subsumed, while oral anti-
hyperglycemic agents start with the code ‘‘A10B’’.
Following Waugh et al. [3], a drug was considered as ‘‘newer’’ if
it belonged to the following groups of glucose lowering drugs:
Regional Differences in Anti-Hyperglycemic Treatment
PLOS ONE | www.plosone.org 2 June 2014 | Volume 9 | Issue 6 | e99773
I) Insulin analogues: Lispro (A10AB04, A10AC04), combina-
tions with Lispro (A10AD04), Aspart (A10AB05, A10AC05,
A10AD05), Glulisine (A10AB06), Glargine (A10AE04),
Detemir (A10AE05).
II) Newer oral anti-hyperglycemic medications: thiazolidine-
diones (A10BG: e.g. Rosiglitazone, Pioglitazone), glinides
(A10BX: e.g. Repaglinide, Nateglinide), DPP4-inhibitors
(A10BH), and combinations of thiazolidinediones or glinides
with metformin or glimepiride (A10BD03-A10BD08).
All other anti-hyperglycemic drugs were classified as older
medications.
The examined newer anti-hyperglycemic drugs have been
introduced shortly before or after year 2000. Since then, both
older and newer drugs were available for anti-hyperglycemic
treatment in Germany. DPP4-Inhibitors were introduced in 2007
and were not yet used by patients from both cohorts (time of
examination 2005/2006–2008). Furthermore, pioglitazone was
under restriction only after 2011, so that this drug was still
reimbursed by statutory health insurances at the time of both
surveys.
Socioeconomic measures
In our main analysis, we used educational level as indicator of
socioeconomic position, as many analyses [19–21]. Educational
level was assessed by highest self-reported schooling degree
achieved at baseline examination. A dichotomous variable was
created to indicate high and low educational level. Low
educational level was assumed if only junior high school was
attended or if no schooling degree has been achieved. High
educational level was defined by completed high (higher educa-
tional entrance qualification, advanced technical college entrance)
or middle educational graduation (general certificate of secondary
education or polytechnic grammar school, POS). In other words,
completed 10 years of schooling or more were classified as high
educational level.
In the former German Democratic Republic (GDR), a POS
degree before 1965 was obtained after 8 years of schooling. In
1965 the schooling system was changed and 10 years were needed
to achieve a POS degree. Three participants with a POS degree
(in HNR) born before 1951 were excluded from the analysis,
because of the limited comparability.
Information on monthly net household income as well as on
household size was obtained from personal interviews. Following
the example of earlier studies within the DIAB-CORE consor-
tium, we calculated the equivalent income according to the
Luxembourg Income Study (income/household size) [22,23].
Anthropometry, blood pressure, HbA1c, history of stroke,
myocardial infarction, and cardiovascular medication
Body mass index was calculated from measured height and
weight. In both studies, systolic and diastolic blood pressure was
measured by trained personal using a validated automatic device
(OMRON HEM 705-CP, OMRON Corporation, Hoofdorp, The
Netherlands). Three independent blood pressure measurements
were taken with a 3-minute pause in a sitting position on the right
arm. The mean of second and third measurement was used for the
current analyses.
In HNR, HbA1c was measured by latex agglutination inhibition
in EDTA whole blood using the ADVIA Chemistry System. In
KORA F4, EDTA plasma was analyzed by high performance
liquid chromatography using Menarini HA-8160. Due to these
different assessment methods HbA1c values were not considered
as statistically comparable between both studies. Nonetheless, we
included HbA1c measurements in the regression models especially
to determine its confounding effect in stratified analyses.
History of stroke and myocardial infarction was assessed by
participant’s self-reports (‘‘Did you ever have a myocardial
infarction/stroke diagnosed by a physician?’’). Cardiovascular
treatment was taken from self-reported medication as described
above. ATC code ‘‘C’’ indicated any cardiovascular treatment.
Insurance status, family status and lifestyle measures
Insurance status was assessed in both studies according to
patients’ self-reports. A binary variable was created separating
persons who were privately health insured from those who were
statutory health insured. The family situation and marital status
were assessed and a dichotomous variable was created for living
with a partner (yes/no).
Smoking habits were assessed in an interview situation in both
studies. A dichotomous variable was created separating current
from ex- and never-smokers. Current smokers needed to smoke at
least one cigarette per day. Ex-smokers had smoked at least one
cigarette per day in the past, but had quit smoking at least one year
ago. Never-smokers had never smoked or had smoked only
occasionally (,1 cigarette / day).
In KORA F4, the physical activity level was estimated based on
self-reported time per week spent on sports activities during leisure
time in summer and winter. Participants were considered
physically active if they participated in sports for at least one
hour per week and as inactive if they were active for ,1 hour per
week in summer or winter. In HNR, individuals were also
considered as active, if they were active for at least one hour per
week but without differentiation between summer and winter
activity.
Thresholds for high alcohol consumption were defined for men
and women (.20 g/day in women and .40 g/day in men). The
calculation of daily alcohol amount was based on weekly
consumption of beer, wine and liquor according to Kraus and
Augustin [24].
Statistical analysis
For descriptive analyses, means and standard deviations of all
continuous variables as well as proportions and numbers of all
categorical covariates were computed in the total population as
well as stratified by study and educational level. Likewise,
proportions of treatment with anti-hyperglycemic pharmaceutical
components were calculated.
We performed two evaluations of the association between
educational level and regional disparities with anti-hyperglycemic
medication: First, the association with any medication was
examined and prevalence ratios (PR) were estimated following
Zhou et al. by multivariable poisson regression models with a
robust error variance using log link function [25]. Second, this
association was examined with newer medication as outcome
among participants with any anti-hyperglycemic medication. This
methodological approach was chosen due to a high prevalence of
both outcomes, whereby an odds ratio calculated from logistic
regression models would considerably overestimate the true effect
[26]. Univariable models for study, educational level (as main
predictors) and all potential confounders were fitted respectively.
Additionally, three models were fitted adjusting for (1) age at
examination (one year difference in the age groups compared), sex
(male vs. female), diabetes duration (years); (2) variables of model 1
plus BMI (kg/m2), diastolic and systolic blood pressure (mmHG),
HbA1C (% and mmol/mol), stroke (yes vs. no) and myocardial
infarction (yes vs. no) in the past; (3) variables of model 2 plus
lifestyle factors, i.e. living with a partner (yes vs. no), sports
Regional Differences in Anti-Hyperglycemic Treatment
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activities (yes vs. no), current smoking (yes vs. no), high alcohol
consumption (yes vs. no) and private health insurance (vs. statutory
health insurance). In sensitivity analyses, all analyses were repeated
with income as measure for socioeconomic position. All models
were performed in the total population with type 2 diabetes as well
as stratified by region.
Analyses were performed using SAS statistical software version
9.3 (SAS Institute Inc., Cary, NC, USA).
Results
Description of the study population
Table 1 shows the characteristics and patterns of anti-
hyperglycemic treatment of participants with type 2 diabetes
stratified by region and education. In comparison to KORA F4,
participants from HNR more frequently had a higher education,
were slightly younger at examination and at diagnosis of diabetes,
had a shorter duration of diabetes, had higher systolic and diastolic
blood pressure measurements along with a slightly lower BMI.
Male preponderance was particularly seen among participants
with high education in both studies. Living with a partner and
smoking were more common in HNR while high alcohol
consumption, sports activities and being privately health insured
were more frequent in KORA F4 especially in participants with
high education. Regarding diabetes related complications, stroke
and cardiovascular treatment were more common in HNR while
percentages for myocardial infarction were similar in both studies.
Individuals with low education more often had these complications
in both studies. For HbA1c (KORA F4: plasma; HNR: whole
blood), similar values were found in all strata.
Treatment groups
About three fourths of all individuals (N = 499) were treated
with any anti-hyperglycemic treatment among these 47.7% with
metformin, 25.4% with sulfonylureates, and 20.1% with any
insulin. In KORA F4, more participants received anti-hypergly-
cemic treatment than in HNR, in particular individuals with low
education. This pattern was similar for oral anti-hyperglycemic
treatment and for treatment with any insulin.
Almost one fourth of those receiving any anti-hyperglycemic
medication were treated with newer anti-hyperglycemic drugs.
This proportion was higher in KORA F4 than in HNR. In
contrast to any anti-hyperglycemic treatment, the frequency of
newer anti-hyperglycemic treatment was substantially higher
among participants with high education. These findings were
consistent when considering solely newer insulin analogues as well
as newer oral drugs.
Prevalence of insulin as monotherapy did not differ between
both studies, while this proportion was substantially higher among
individuals with low education in KORA F4 (13.8% vs. 2.0%)
(data not shown).
Determinants of any anti-hyperglycemic treatment in the
total population
The results of regression models modeling factors associated
with any anti-hyperglycemic medication are shown in table 2. In
univariable analysis, study location was associated with anti-
hyperglycemic medication in such a way that KORA F4
participants had a moderate but significantly higher probability
to receive anti-hyperglycemic drugs than participants in HNR
(PR:1.14, 95% CI: 1.05–1.24). Adjustment for education, age at
examination, sex, diabetes duration, BMI, diastolic and systolic
blood pressure, HbA1C, clinical variables (previous myocardial
infarction or stroke), lifestyle factors (living with partner, sports
activities, smoking, alcohol consumption) and insurance status
(PR: 1.12; 1.02–1.22) did not alter the results substantially.
Participants with low educational level tended to have a higher
albeit not statistically significant probability to receive anti-
hyperglycemic medication in univariable analysis (PR: 1.10;
0.99–1.22) as well as in the fully adjusted model (PR 1.10; 0.98–
1.23).
In multivariable models, participants with longer diabetes
duration had a higher probability to be treated with anti-
hyperglycemic drugs (PR and corresponding 95% CI for each
year increase in diabetes duration: 1.01; 1.01–1.02). Likewise, the
elevation of one unit of HbA1C-value increased this probability
(PR(%): 1.12; 1.08–1.16; (mmol/mol): 1.010; 1.007–1.014).
Demographic variables such as age and sex as well as all other
clinical variables (i.e. blood pressure, previous stroke and
myocardial infarction), BMI, lifestyle factors (living with partner,
sports activities, current smoker, high alcohol consumption) as well
as insurance status had no impact on receiving anti-hyperglycemic
treatment.
When stratifying analysis for study region, lower educational
level was positively associated with any anti-hyperglycemic
medication in both studies in the fully adjusted model, however
not reaching level of significance neither in KORA F4 (PR:1.17;
0.98–1.39) nor in HNR (PR: 1.08; 0.93–1.26). In contrast, the
associations with diabetes duration and HbA1C remained
significant in both study regions. Interaction between education
and study region was not significant (p-value for multivariable
adjusted interaction term: p = 0.68).
Determinants of newer anti-hyperglycemic treatment
among those with any anti-hyperglycemic treatment
Table 3 shows the results of the regression models modeling
factors associated with newer anti-hyperglycemic medication
among the 499 participants with any anti-hyperglycemic medica-
tion.
In univariable models, KORA F4 participants had a signifi-
cantly higher probability to receive newer glucose lowering drugs
(PR 1.43; 95% CI: 1.05–1.96). This association remained
significant after adjustment for all potential confounders (PR:
1.52; 1.10–2.11). In contrast, persons with low educational level
were significantly less frequently treated with newer anti-hyper-
glycemic drugs compared to those with high education (univari-
able PR: 0.66; 0.48–0.91), which was also true after multivariable
adjustment: (PR: 0.68; 0.47–0.996).
In fully adjusted models diabetes duration (PR: 1.03; 1.02–1.05),
HbA1C (PR: 1.02; 95% CI: 1.004–1.03) and being private health
insured (PR: 2.05; 95% CI: 1.25–3.36) was also positively
associated with newer anti-hyperglycemic medication. Again, age
and sex were not associated with newer anti-hyperglycemic
treatment as well as BMI, blood pressure, previous myocardial
infarction and lifestyle factors.
After stratification for study region, the probability to receive a
newer anti-diabetic treatment among participants with lower
education was significantly lower only in HNR (KORA F4: 0.82;
95% CI: 0.50–1.37; HNR: 0.57; 0.33–0.98). Regarding covariates,
an inconsistent pattern was found. In HNR, HbA1C (PR (%):
1.27; 1.05–1.54; (mmol/mol): 1.023; 1.005–1.041) and being
privately health insured were positively associated with newer anti-
hyperglycemic treatment (PR: 2.44; 1.23–4.81), while in KORA
F4, diabetes duration increased this probability (PR: 1.05; 1.03–
1.08). In contrast, negative associations were observed in KORA
F4 with diastolic blood pressure (PR for one unit increase: 0.94;
0.91–0.98) as well as previous myocardial infarction (PR: 0.25;
Regional Differences in Anti-Hyperglycemic Treatment
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0.07–0.87). The interaction term between education and study
region was not significant (p = 0.42).
As further clinical variables, HbA1 and diabetes duration
increased the possibility to receive (any or newer) anti-hypergly-
cemic medication in both studies. Adding both variables to the
models did not confound the association of anti-hyperglycemic
treatment with region or SES.
Sensitivity analysis
When we used equivalent income (income/household members)
instead of education, the probability of receiving any anti-
hyperglycemic medication was not associated with SES in the
whole population as well as in stratified analyses (PR for an
increase of 100J income: whole population 1.00; 0.99–1.01;
KORA F4 0.99; 0.98–1.005; HNR 1.00; 0.99–1.01). Income was
also associated with newer anti-hyperglycemic treatment in
KORA F4 (PR for an increase of 100J income: whole population
1.02; 0.996–1.04; KORA F4 1.06; 1.03–1.09; HNR 1.00; 0.98–
1.03). In the fully adjusted models PRs of all other variables did
not materially change (data not shown).
Discussion
Main findings and implications
In this cross-sectional examination based on pooled individual
data from two population-based studies – one in the south (KORA
F4) and one in the west (HNR) of Germany – the probability to
receive anti-hyperglycemic drugs as well as to receive newer
glucose lowering drugs such as insulin analoga, TZDs, or glinides
was substantially higher in the south of Germany. Regarding
socioeconomic differences, individuals with lower educational level
tended to have a higher probability to receive anti-hyperglycemic
drugs than their better educated counterparts. However, the
association was not significant. Among those with any anti-
hyperglycemic medication, individuals with lower educational
level had a significantly lower probability to receive newer anti-
hyperglycemic drugs than their better educated counterparts. In
region-stratified analyses the latter effect was only significant in
HNR, however, the overall pattern was similar in both studies.
HbA1c and diabetes duration were further independent predictors
for anti-hyperglycemic medication in both studies. However, this
association could not explain the regional differences in anti-
hyperglycemic medication and the difference in high and low SES
groups (especially HNR). Furthermore, the regional and socio-
economic differences remained after adjusting for other individual
factors available for analysis (such as BMI, lifestyle or complica-
tions such as myocardial infarction and stroke).
Importantly, the older anti-hyperglycemic drug metformin
remains the oral drug of first choice in current clinical guidelines
[27]. These guideline recommendations emphasize the need for
individualized treatment decisions which are influenced by clinical
decisions as well as other patient characteristics and which in
consequence can be responsible for the prescription of newer anti-
hyperglycemic drugs. As an example, age, Hba1c levels, expected
treatment efforts, diabetes related complications, and co-morbid-
ities of patients merit attention. Disadvantages of metformin such
as gastrointestinal side effects, vitamin B12 deficiency, and chronic
kidney disease may guide treatment choice towards newer
medications [27]. A decision for glitazone includes severe
adipositas (insulin resistance) [28]. Furthermore, before 2011,
TZDs (pioglitazone) were not recommended for patients with
cardiovascular or hepatic disease. However, since 2011, TZDs are
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Table 2. Factors associated with any anti-hyperglycemic medication (N = 662)*.
Univariable Model Total KORA HNR
Prevalence Ratio (95% CI)
Study (KORA vs. HNR) 1.14(1.05–1.24) ------ ------
Low educational level vs. high 1.10(0.99–1.22) 1.16(0.97–1.40) 1.07(0.94–1.22)
Age at examination (years) 1.00(1.00–1.01) 1.01(1.00–1.02) 1.00(0.99–1.01)
Male sex vs. female 1.01(0.93–1.11) 1.04(0.91–1.19) 1.01(0.90–1.13)
Diabetes duration (years) 1.01(1.01–1.02) 1.01(1.01–1.02) 1.01(1.01–1.02)
BMI (kg/m2) 1.01(1.00–1.02) 1.01(1.00–1.02) 1.01(1.00–1.02)
Diastolic blood pressure (mmHg) 1.00(0.99–1.00) 0.99(0.99–1.00) 1.00(0.99–1.00)
Systolic blood pressure (mmHg) 1.00(1.00–1.00) 1.00(0.99–1.00) 1.00(1.00–1.00)
HbA1c (mmol/mol) 1.01(1.01–1.01) 1.01(1.00–1.01) 1.01(1.01–1.02)
Previous stroke (yes vs. no) 0.94(0.78–1.14) 1.08(0.85–1.38) 0.91(0.72–1.16)
Previous MI (yes vs. no) 1.01(0.88–1.17) 1.03(0.85–1.26) 1.00(0.83–1.20)
Living with partner (yes vs. no) 0.95(0.86–1.05) 0.89(0.79–1.02) 1.00(0.86–1.15)
Sports activity ,1 h a week (yes vs .no) 1.05(0.96–1.15) 1.15(1.01–1.32) 1.02(0.91–1.14)
Current smoker (yes vs. no) 0.91(0.80–1.04) 1.00(0.82–1.22) 0.90(0.76–1.06)
High alcohol consumption (yes vs. no) 1.05(0.91–1.22) 1.00(0.82–1.22) 1.05(0.85–1.30)
Private insured (vs. statutory health insured) 1.03(0.86–1.22) 1.07(0.88–1.30) 0.97(0.73–1.27)
Basic model
Low educational level vs. high 1.09(0.98–1.21) 1.14(0.95–1.36) 1.08(0.94–1.23)
Study (KORA vs. HNR) 1.13(1.03–1.22) ------ ------
Age at examination (years) 1.00(0.99–1.00) 1.00(0.99–1.01) 1.00(0.99–1.00)
Male sex vs. female 1.02(0.93–1.11) 1.05(0.93–1.19) 1.00(0.89–1.12)
Diabetes duration (years) 1.01(1.01–1.02) 1.01(1.01–1.02) 1.02(1.01–1.02)
‘‘Clinical model’’: Basic model + BMI + comorbidities + Blood Pressure**
Low educational level vs. high 1.08(0.97–1.21) 1.17(0.98–1.39) 1.06(0.93–1.22)
Study (KORA vs. HNR) 1.13(1.03–1.23) ------ ------
Age at examination (years) 1.00(0.99–1.01) 1.00(0.99–1.01) 1.00(0.99–1.01)
Male sex vs. female 1.04(0.95–1.14) 1.11(0.96–1.29) 1.01(0.90–1.13)
Diabetes duration (years) 1.01(1.01–1.02) 1.01(1.00–1.02) 1.01(1.01–1.02)
BMI (kg/m2) 1.01(1.00–1.01) 1.01(1.00–1.02) 1.00(0.99–1.01)
Diastolic blood pressure (mmHg) 1.00(0.99–1.00) 1.00(0.99–1.00) 1.00(0.99–1.00)
Systolic blood pressure (mmHg) 1.00(1.00–1.00) 1.00(0.99–1.00) 1.00(1.00–1.01)
HbA1c (mmol/mol) 1.01(1.01–1.01) 1.01(1.00–1.01) 1.01(1.01–1.01)
Previous stroke (yes vs. no) 0.92(0.76–1.12) 1.02(0.81–1.30) 0.90(0.71–1.15)
Previous MI (yes vs. no) 0.98(0.85–1.12) 0.92(0.75–1.13) 1.01(0.84–1.22)
Full model: ‘‘Clinical model’’+ Lifestyle + Insurance status***
Low educational level vs. high 1.10(0.98–1.23) 1.17(0.98–1.39) 1.08(0.93–1.26)
Study (KORA vs. HNR) 1.12(1.02–1.22) ------ ------
Age at examination (years) 1.00(0.99–1.01) 1.00(0.99–1.01) 1.00(0.99–1.01)
Male sex vs. female 1.05(0.95–1.17) 1.12(0.95–1.31) 1.02(0.90–1.17)
Diabetes duration (years) 1.01(1.01–1.02) 1.01(1.00–1.02) 1.01(1.00–1.02)
BMI (kg/m2) 1.00(1.00–1.01) 1.01(1.00–1.02) 1.00(0.99–1.01)
Diastolic blood pressure (mmHg) 1.00(0.99–1.00) 1.00(0.99–1.01) 1.00(0.99–1.01)
Systolic blood pressure (mmHg) 1.00(1.00–1.00) 1.00(0.99–1.00) 1.00(1.00–1.01)
HbA1c (mmol/mol) 1.01(1.01–1.01) 1.01(1.00–1.01) 1.01(1.01–1.02)
Previous stroke (yes vs. no) 0.90(0.73–1.11) 1.02(0.80–1.30) 0.87(0.67–1.13)
Previous MI (yes vs. no) 1.01(0.89–1.16) 0.93(0.75–1.15) 1.08(0.90–1.29)
Living with partner (yes/no) 0.98(0.88–1.09) 0.92(0.80–1.06) 1.02(0.87–1.20)
Sports activity ,1 h a week (yes vs. no) 1.02(0.93–1.11) 1.09(0.97–1.23) 0.98(0.87–1.10)
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We controlled for some of these variables in our study.
However, detailed information on complications other than
myocardial infarction and stroke were not available in a highly
comparable way for a pooled analysis, so that individual treatment
decisions were irreproducible. Nevertheless, the south of Germany
is a region with lower overall mortality, lower blood pressure and
lower type 2 diabetes prevalence than the west [29,30]. Thus,
given the overall trend for a healthier population in the south,
mere clinical decisions are not likely to have caused the regional
differences we found.
We could not find any explanations for our findings. In
Germany, as well as in most western European countries, almost
all individuals are members of a health insurance and have almost
free access to the majority of medical services. Exceptions are
medications given as over-the-counter medication and for diseases
with low severity, e.g. cold, which are paid by the patients.
Overall, private expenditures account for about 15% of the health
care expenditures [7]. Diabetes treatment in Germany should be
rather standardized, in particular since the introduction of disease
management programs. However, regional differences with
respect to health care services are likely. For example in more
rural regions, the availability of specialized diabetes care might be
lower compared to urban areas [31]. Respective analyses are
planned for the future. In addition, local health care practice
including e.g. the screening frequency or generally the awareness
of the disease in a population might affect the proportion of
undiagnosed diabetes in a region possibly also causing regional
differences in sample characteristics.
It could be argued that regional and social discrepancies for
newer glucose lowering drug use could be mediated at least in part
by health insurance status. Persons with a high income or those
who are self-employed are free to take out private health insurance
covering extra services of medical care. While statutory health
insurances impose a limit on GPs and specialized diabetes
practitioners for prescriptions, private health insurance companies
are more likely to accept the higher costs for newer medications.
Besides cost reasons, individuals with private health insurance
might differ from those insured statutorily in such a way that they
might participate more actively in treatment decisions and claim
for newer medications.
In our study, we found a higher proportion of anti-hypergly-
cemic drug intake among privately health insured persons
compared to statutorily health insured participants, which was
significantly increased for newer anti-hyperglycemic medication.
Adjusting for health insurance status did not alter the association
between education and anti-hyperglycemic medication substan-
tially. These findings could emphasize that persons with a higher
education in general might receive newer drugs more frequently
irrespective of their status of insurance.
Interestingly, when we used equivalent income as an indicator
for socioeconomic status, the probability for receiving any anti-
hyperglycemic medication was not associated with SES. However,
there was an association with newer anti-hyperglycemic medica-
tion which is also more expensive. Similar results were reported in
a recent study from Sweden, where drug utilization was associated
with education, but not with income [32]. The authors could not
explain their findings. They suggest that medication may be
influenced particularly by the interaction between physician and
patient, and that this interaction may depend on patients’
education more than on patients’ income level.
Comparison to other studies
Despite the interest in geographic differences in health care
spending and treatment patterns, literature on the contribution of
structural deprivation and individual socioeconomic status on anti-
hyperglycemic treatment is scarce. Social gradients in treatment
with certain medications or diet alone have been found earlier in a
Canadian study [33]. Prescription of metformin and sulfonylureas
was higher in lower income groups, while ‘‘diet-alone’’ was more
often treatment option in higher income quintiles than in lower
ones. Another Canadian study based on reimbursement data
indicated, that high income groups were more likely to receive
restricted medications such as thiazolidinediones (TZDs) com-
pared to low income groups [6], similar to our study. The authors
could not explain their finding. Regional disparities in prescription
patterns based on insurance data have been described earlier for
the prescription prevalence of antibiotic use. A recent German
study showed a regional variation of 19–53% of antibiotic use in
children which was partly explained by regional deprivation
(especially by regional income and occupational deprivation) [34].
Structural differences of health care supply which have recently
been reported for Germany might also be relevant for our findings
[35]. The authors analyzed if regional health care utilization met
the expected needs (equity index = 1). They could show that
factors of health care supply such as physician density and
physician contacts explained 49% of health care utilization. A high
physician density and a high number of physician contacts was
associated with a higher health care utilization beyond the
expected needs (equity index below 1). On the other hand, a high
number of social welfare recipients in a region was associated with
a lower utilization. Regarding our study areas, for Augsburg and
its rural surroundings a low equity index was calculated (utilization
exceeded the needs) while the equity index was close to 1 in the
urban areas of the HNR study. Therefore, structural differences by
region such as a higher physician density and a higher number of
Table 2. Cont.
Univariable Model Total KORA HNR
Prevalence Ratio (95% CI)
Current smoker (yes vs. no) 0.90(0.79–1.04) 1.00(0.81–1.24) 0.86(0.72–1.02)
High alcohol consumption(yes vs. no) 1.05(0.90–1.24) 1.03(0.85–1.24) 1.14(0.88–1.47)
Private insured (vs. statutory health insured) 1.07(0.89–1.27) 1.06(0.85–1.32) 1.04(0.78–1.38)
*Results are prevalence ratios (95%CI) calculated from poisson regression models with robust error variance as proposed by Zhou et al.[25]
Abbreviations: KORA = Cooperative Health Research in the Region of Augsburg study; HNR = Heinz Nixdorf Recall study; MI = myocardial infarction.
** 10 missing values (in HbA1c)
*** 37 missing values
doi:10.1371/journal.pone.0099773.t002
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Table 3. Factors associated with newer anti-hyperglycemic medication among participants with any anti-hyperglycemic
medication (N = 499) (newer vs. older medication)*.
Univariable Model Total KORA HNR
Prevalence Ratio (95% CI)
Study (KORA vs. HNR) 1.43(1.05–1.96) ------ ------
Low educational level vs. high 0.66(0.48–0.91) 0.78(0.47–1.31) 0.57(0.38–0.86)
Age at examination (years) 1.00(0.98–1.02) 1.00(0.97–1.03) 0.99(0.96–1.02)
Male sex vs. female 0.95(0.69–1.30) 0.72(0.45–1.15) 1.17(0.76–1.81)
Diabetes duration (years) 1.04(1.03–1.06) 1.06(1.04–1.08) 1.03(1.01–1.05)
BMI (kg/m2) 1.02(0.99–1.04) 1.03(0.99–1.07) 1.01(0.97–1.04)
Diastolic blood pressure (mmHg) 0.98(0.97–1.00) 0.96(0.94–0.99) 1.00(0.98–1.02)
Systolic blood pressure (mmHg) 1.00(0.99–1.00) 0.99(0.98–1.01) 1.00(0.99–1.01)
HbA1c (mmol/mol) 1.02(1.01–1.03) 1.01(0.99–1.03) 1.02(1.01–1.03)
Previous stroke (yes vs. no) 0.38(0.13–1.12) n.e. 0.58(0.20–1.70)
Previous MI (yes vs. no) 0.81(0.45–1.44) 0.37(0.10–1.37) 1.14(0.60–2.17)
Living with partner (yes vs. no) 1.07(0.72–1.58) 1.35(0.74–2.47) 0.95(0.56–1.59)
Sports activity ,1 h a week(yes vs. no) 1.02(0.74–1.41) 0.87(0.54–1.39) 1.20(0.77–1.87)
Current smoker (yes vs. no) 0.77(0.46–1.26) 0.32(0.09–1.22) 1.05(0.60–1.82)
High alcohol consumption (yes vs. no) 1.14(0.67–1.94) 0.86(0.39–1.91) 1.33(0.65–2.72)
Private insured (vs. statutory health insured) 2.00(1.28–3.12) 1.49(0.77–2.87) 2.40(1.31–4.39)
Basic model
Low educational level vs. high 0.60(0.44–0.83) 0.62(0.37–1.02) 0.56(0.37–0.87)
Study (KORA vs. HNR) 1.50(1.10–2.03) ------ ------
Age at examination (years) 0.99(0.97–1.01) 0.98(0.95–1.01) 0.99(0.96–1.02)
Male sex vs. female 0.87(0.65–1.18) 0.66(0.43–1.02) 1.07(0.70–1.63)
Diabetes duration (years) 1.05(1.03–1.06) 1.07(1.04–1.09) 1.04(1.02–1.06)
‘‘Clinical model’’: Basic model + BMI + comorbidities + Blood Pressure**
Low educational level vs. high 0.61(0.44–0.85) 0.77(0.47–1.24) 0.52(0.33–0.80)
Study (KORA vs. HNR) 1.48(1.08–2.02) ------ ------
Age at examination (years) 0.99(0.97–1.02) 0.96(0.93–1.00) 1.01(0.98–1.05)
Male sex vs. female 0.94(0.67–1.31) 0.94(0.57–1.54) 1.05(0.67–1.65)
Diabetes duration (years) 1.04(1.02–1.06) 1.06(1.03–1.08) 1.03(1.01–1.05)
BMI (kg/m2) 1.01(0.98–1.04) 1.04(1.00–1.08) 1.00(0.96–1.03)
Diastolic blood pressure (mmHg) 0.99(0.96–1.01) 0.95(0.91–0.98) 1.01(0.98–1.04)
Systolic blood pressure (mmHg) 1.00(0.99–1.01) 1.01(0.99–1.03) 1.00(0.98–1.01)
HbA1c (mmol/mol) 1.02(1.01–1.03) 1.01(0.99–1.03) 1.03(1.01–1.04)
Previous stroke (yes vs. no) 0.30(0.08–1.15) n.e. 0.47(0.13–1.70)
Previous MI (yes vs. no) 0.78(0.43–1.42) 0.26(0.07–0.98) 1.30(0.66–2.57)
Full model: ‘‘Clinical model’’+ Lifestyle + Insurance status***
Low educational level vs. high 0.68(0.47–1.00) 0.82(0.50–1.37) 0.57(0.33–0.98)
Study (KORA vs. HNR) 1.52(1.10–2.11) ------ ------
Age at examination (years) 0.99(0.97–1.02) 0.96(0.93–1.00) 1.01(0.98–1.05)
Male sex vs. female 0.86(0.59–1.25) 0.78(0.45–1.35) 1.01(0.59–1.72)
Diabetes duration (years) 1.03(1.02–1.05) 1.05(1.03–1.08) 1.02(1.00–1.05)
BMI (kg/m2) 1.02(0.99–1.05) 1.04(0.99–1.08) 1.01(0.97–1.05)
Diastolic blood pressure (mmHg) 0.99(0.96–1.01) 0.94(0.91–0.98) 1.01(0.97–1.04)
Systolic blood pressure (mmHg) 1.00(0.99–1.02) 1.01(0.99–1.03) 1.00(0.98–1.02)
HbA1c (mmol/mol) 1.02(1.00–1.03) 1.02(1.00–1.04) 1.02(1.00–1.04)
Previous stroke (yes vs. no) 0.17(0.02–1.17) n.e. 0.30(0.04–2.03)
Previous MI (yes vs. no) 0.82(0.45–1.50) 0.25(0.07–0.87) 1.42(0.71–2.85)
Living with partner (yes vs. no) 1.29(0.83–2.00) 1.57(0.84–2.94) 0.97(0.52–1.83)
Sports activity ,1 h a week(yes vs. no) 1.03(0.74–1.43) 0.88(0.55–1.39) 1.12(0.69–1.81)
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physician contacts might be important factors contributing to the
higher overall anti-hyperglycemic medication use in KORA F4
which should be addressed in further studies.
Strenghts and limitations
Our study has several limitations. First, we could not examine if
direct contracts between general practitioners and health insur-
ance companies, which vary across regions, might have had an
impact on treatment decisions. Second, as described above,
clinical information on participants was limited. Thus, we could
not evaluate if treatment patterns follow clinical guidelines and
correspond with indications for newer treatment options. Further-
more, cases with cardiovascular events (myocardial infarction,
stroke) were too low in some subgroups so that statistical power
was insufficient to detect associations with treatment decisions.
Finally, some variables, such as HbA1c, were not exactly
comparable between the two studies.
The strengths of our study are highly standardized measure-
ment techniques carried out by trained personnel (e.g. for
anthropometry and blood pressure) and the application of very
similar, standardized interviews and questionnaires. Sampling
frames of both population-based studies aimed for a high
representativeness of the data. Furthermore, both studies used a
similar scanning system to assign unique pharmaceutical identifiers
(ATC codes) to the medication packages brought to the interview
date.
In conclusion, we found regional disparities in any and in newer
anti-hyperglycemic treatment in Germany. Lower social status was
also associated with a lower probability to receive newer anti-
hyperglycemic drugs which was especially observed in the Ruhr
area (HNR). Overall, these differences were not explained by age,
sex, BMI, and lifestyle factors such as sports activities or smoking
as well as insurance status. Of note, the disparities in treatment
with newer anti-hyperglycemic drugs we found do not implicate
regional or social disparities in quality of care. Further research is
needed to explain these findings. Especially, studies are warranted
that include a larger number of patients and further geographic
regions.
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